Neuromyelitis optica (NMO) is a devastating neuroinflammatory disorder that specifically targets the spinal cord and optic nerves. Aquaporin-4 (AQP4) is the target of the NMO-IgG biomarker
A 21-year-old right-handed woman suffered cervical myelitis in 1971, followed by two episodes of bilateral optic neuritis and four relapses of thoracic or lumbar myelitis through 1998. Her initial brain MRI in 1989 revealed no abnormality, which met the MRI criteria for multiple sclerosis. In 2009, her serum anti-aquaporin-4 antibody was found to be positive, and a diagnosis of relapsing neuromyelitis optica (NMO) was made on the basis of current diagnostic criteria
OBJECTIVE: To investigate serum uric acid (UA) levels and related clinical characteristics of neuromyelitis optica (NMO). METHODS: The serum uric acid levels were measured in 65 patients with NMO, compared to control groups which were 76 cases with multiple sclerosis (MS), 126 cases with cerebral vascular diseases (CVD) and 130 healthy controls (HC). The disability severity in NMO was assessed by the Expanded Disability Status Scale (EDSS).
OBJECTIVE:To investigate the characteristics of the linear lesions and longitudinally extensive spinal cord (LESC) lesions in Chinese patients with neuromyelitis optica (NMO).